as 05-20-2024 4:00pm EST
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | BEDFORD |
Market Cap: | 7.0M | IPO Year: | N/A |
Target Price: | $10.00 | AVG Volume (30 days): | 15.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.41 | EPS Growth: | N/A |
52 Week Low/High: | $1.55 - $2.91 | Next Earning Date: | 05-10-2024 |
Revenue: | $11,684,000 | Revenue Growth: | 82.28% |
Revenue Growth (this year): | -3.07% | Revenue Growth (next year): | 1.00% |
PULM Breaking Stock News: Dive into PULM Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Simply Wall St.
8 days ago
PR Newswire
10 days ago
PR Newswire
2 months ago
ACCESSWIRE
4 months ago
PR Newswire
4 months ago
GlobeNewswire
4 months ago
GuruFocus.com
4 months ago